Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MDD011
MIFTS: 61

Mood Disorder

Categories: Mental diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mood Disorder

About this section

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 11 14 16 75
Mood Disorders 53 41 43 14 71 33
Episodic Mood Disorder 11 71

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:3324
MeSH 43 D019964
NCIt 49 C92200
SNOMED-CT 68 46206005
UMLS 71 C0525045 C1456434
Sources

Summaries for Mood Disorder

About this section

MedlinePlus: 41 Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.

MalaCards based summary: Mood Disorder, also known as mood disorders, is related to major depressive disorder and schizoaffective disorder, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Signal Transduction and GPCR downstream signalling. The drugs Lithium carbonate and Valproic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and pituitary, and related phenotypes are nervous system and homeostasis/metabolism

Disease Ontology: 11 A cognitive disorder that involves a disturbance in mood as the predominant underlying feature.

Wikipedia: 75 A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and... more...
Sources

Related Diseases for Mood Disorder

About this section

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 643)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 32.6 TPH2 TPH1 TH TACR1 SLC6A4 NPY
2 schizoaffective disorder 32.5 SLC6A4 HTR2A HTR1A DRD4 DRD2 DISC2
3 bipolar disorder 32.4 TPH2 TPH1 TH TACR1 SLC6A4 MAOA
4 delusional disorder 32.4 HTR2A HTR1A DRD4 DRD2 DISC1 COMT
5 dysthymic disorder 32.3 SLC6A4 MAOA HTR2A HTR1A DRD4 CRH
6 postpartum depression 32.3 SLC6A4 MAOA HTR2A HTR1A CRH COMT
7 atypical depressive disorder 32.2 SLC6A4 MAOB MAOA HTR2A HTR1A CRH
8 bipolar i disorder 31.4 SLC6A4 HTR2A HTR1A DRD2 DISC1 COMT
9 personality disorder 31.4 TPH2 TPH1 TH SLC6A4 MAOB MAOA
10 psychotic disorder 31.3 TPH2 TPH1 TH SLC6A4 NPY MAOB
11 anxiety 31.3 TPH2 TPH1 TH SLC6A4 NPY MAOB
12 alcohol use disorder 31.3 SLC6A4 NPY MAOA DRD4 DRD2 CRH
13 endogenous depression 31.2 TPH2 TPH1 SLC6A4 MAOA HTR2A HTR1A
14 borderline personality disorder 31.1 TPH2 TPH1 TH SLC6A4 MAOA HTR2A
15 cyclothymic disorder 31.1 SLC6A4 HTR2A HTR1A DRD4 DRD2 DISC1
16 melancholia 31.1 TPH1 SLC6A4 MAOA HTR2A HTR1A CRH
17 agoraphobia 31.1 SLC6A4 MAOA HTR2A HTR1A CRH COMT
18 post-traumatic stress disorder 31.1 SLC6A4 NPY MAOB MAOA HTR2A HTR1A
19 generalized anxiety disorder 31.0 TPH1 SLC6A4 MAOA HTR2A HTR1B HTR1A
20 anorexia nervosa 31.0 TPH1 SLC6A4 NPY MAOA HTR2A HTR1A
21 substance abuse 31.0 SLC6A4 NPY MAOA HTR2A HTR1A DRD4
22 fibromyalgia 31.0 TACR1 SLC6A4 NPY MAOA HTR2A HTR1A
23 chronic fatigue syndrome 31.0 SLC6A4 MAOA HTR1A CRH BDNF
24 movement disease 31.0 TH MAOB HTR2A HTR1A DRD2 COMT
25 eating disorder 31.0 SLC6A4 NPY HTR2A HTR1A DRD2 CRH
26 schizophrenia 30.9 TPH2 TPH1 TH TACR1 SLC6A4 NPY
27 panic disorder 30.9 TPH2 TPH1 TACR1 SLC6A4 NPY MAOA
28 body mass index quantitative trait locus 11 30.9 NPY MAOB MAOA HTR2A HTR1A DRD4
29 attention deficit-hyperactivity disorder 30.9 TPH2 TPH1 TH SLC6A4 NPY MAOB
30 acute stress disorder 30.9 SLC6A4 HTR2A CRH BDNF
31 bowel dysfunction 30.9 TPH1 TACR1 SLC6A4 HTR1A
32 irritable bowel syndrome 30.9 TPH1 TACR1 SLC6A4 HTR2A HTR1A CRH
33 epilepsy 30.9 NPY MAOB MAOA HTR1A CREB1 CNR1
34 social phobia 30.9 SLC6A4 MAOA HTR2A HTR1A DRD2 CRH
35 tardive dyskinesia 30.9 DRD2 DISC1 COMT
36 alcohol dependence 30.8 TPH2 TPH1 TH SLC6A4 NPY MAOB
37 cannabis abuse 30.8 SLC6A4 HTR1A DRD4 DRD2 DISC1 COMT
38 schizophreniform disorder 30.8 HTR2A DRD2 DISC1 COMT BDNF
39 huntington disease 30.8 TH NPY MAOB MAOA DRD2 CREB1
40 separation anxiety disorder 30.8 SLC6A4 MAOA HTR1A DRD4 CRH COMT
41 paine syndrome 30.8 TACR1 SLC6A4 CRH COMT BDNF
42 obsessive-compulsive disorder 30.7 TPH2 TPH1 SLC6A4 NPY MAOB MAOA
43 sleep disorder 30.7 TH SLC6A4 NPY MAOB HTR2A HTR1A
44 parkinsonism 30.7 TH MAOB HTR2A DRD4 DRD2 COMT
45 pervasive developmental disorder 30.7 SLC6A4 HTR2A HTR1A DRD2 DISC1 BDNF
46 fragile x syndrome 30.7 SLC6A4 MAOA CREB1 CNR1 BDNF
47 neurotic disorder 30.7 SLC6A4 MAOA HTR2A HTR1A CRH COMT
48 autism 30.7 SLC6A4 MAOB MAOA HTR2A HTR1A DRD2
49 headache 30.7 SLC6A4 NPY HTR2A COMT BDNF
50 adjustment disorder 30.7 TH SLC6A4 HTR2A HTR1A CRH BDNF

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder
Sources

Symptoms & Phenotypes for Mood Disorder

About this section

UMLS symptoms related to Mood Disorder:


alexithymia; psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.38 BDNF CNR1 COMT CREB1 CRH DISC1
2 homeostasis/metabolism MP:0005376 10.33 BDNF CNR1 COMT CREB1 CRH DISC1
3 behavior/neurological MP:0005386 10.23 BDNF CNR1 COMT CREB1 CRH DISC1
4 normal MP:0002873 10.16 BDNF CNR1 CREB1 CRH DRD2 NPY
5 endocrine/exocrine gland MP:0005379 10.11 BDNF COMT CREB1 CRH DRD2 HTR1B
6 no phenotypic analysis MP:0003012 10.1 BDNF CNR1 CRH DRD2 HTR1A HTR1B
7 cardiovascular system MP:0005385 10.1 COMT CREB1 DISC1 DRD2 HTR1A HTR1B
8 renal/urinary system MP:0005367 10.06 COMT CRH DISC1 DRD2 MAOB NPY
9 adipose tissue MP:0005375 9.98 CNR1 CRH DRD2 HTR1B NPY TPH1
10 respiratory system MP:0005388 9.76 BDNF CREB1 CRH DRD2 TACR1 TH
11 integument MP:0010771 9.28 BDNF CNR1 CRH DRD2 SLC6A4 TACR1
12 taste/olfaction MP:0005394 9.26 BDNF CNR1 DRD2 TPH2
Sources

Drugs & Therapeutics for Mood Disorder

About this section

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 284)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lithium carbonate Approved Phase 4 554-13-2
2
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4
Tranylcypromine Approved, Investigational Phase 4 155-09-9 5530 441233
5
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
6
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
7
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
8
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
9
Amitriptyline Approved Phase 4 50-48-6 2160
10
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
11
Ziprasidone Approved Phase 4 146939-27-7 60854
12
Flupentixol Approved, Investigational, Withdrawn Phase 4 2709-56-0 25137855 5281881 17012
13
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
14
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
15
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
16
Atorvastatin Approved Phase 4 134523-00-5 60823
17
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
18
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
19
Lorazepam Approved Phase 4 846-49-1 3958
20
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
21
Clozapine Approved Phase 4 5786-21-0 2818 135398737
22
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
23
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
24 Trace Elements Phase 4
25 Micronutrients Phase 4
26 Hormones Phase 4
27 Calcium, Dietary Phase 4
28 Monoamine Oxidase Inhibitors Phase 4
29 Anti-Bacterial Agents Phase 4
30 Antioxidants Phase 4
31 Protective Agents Phase 4
32 Calciferol Phase 4
33 Flupenthixol decanoate Phase 4
34 Anticonvulsants Phase 4
35 Estrogens Phase 4
36 Anti-Anxiety Agents Phase 4
37 Antiemetics Phase 4
38 Gastrointestinal Agents Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Antirheumatic Agents Phase 4
41 Anti-Infective Agents Phase 4
42 Cyclooxygenase Inhibitors Phase 4
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4
44 Anti-Inflammatory Agents Phase 4
45 Antiviral Agents Phase 4
46 Expectorants Phase 4
47 Antidotes Phase 4
48 N-monoacetylcystine Phase 4
49 Respiratory System Agents Phase 4
50 GABA Modulators Phase 4

Interventional clinical trials:

(show top 50) (show all 473)
# Name Status NCT ID Phase Drugs
1 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Unknown status NCT03881449 Phase 4
2 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
3 Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms Completed NCT00912535 Phase 4 Quetiapine extended release tablet;Placebo
4 Dynamic Measures of Neurochemistry in Mood Disorders Completed NCT00178828 Phase 4 sertraline;bupropion
5 Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study Completed NCT00177567 Phase 4 lithium carbonate;Depakote-ER;risperidone;olanzapine;paroxetine;bupropion;lamotrigine;venlafaxine;tranylcypromine;mirtazapine
6 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
7 Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Mood Disorders Through Resources Available in Brazilian Public Health Completed NCT02870283 Phase 4 Lithium;Valproic Acid;Carbamazepine
8 Pioglitazone Treatment for Insulin Resistant Patients With Mood Disorders Completed NCT01559857 Phase 4 Pioglitazone;Sugar Pill
9 Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana Completed NCT02593734 Phase 4 olanzapine;risperidone;amitryptaline;fluoxetine
10 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
11 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
12 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
13 Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans Completed NCT00288782 Phase 4 Mirtazapine
14 A Randomized Controlled Trial of Quetiapine for the Treatment of Youth With Co-occurring Substance Use Disorders and Severe Mood Dysregulation Completed NCT02845453 Phase 4 Quetiapine
15 Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia Completed NCT03860597 Phase 4 Memantine;Placebos
16 Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder: A Randomized Controlled Trial Completed NCT04222816 Phase 4 Lithium Carbonate;Sodium chloride
17 Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder Completed NCT00502320 Phase 4 Ramelteon;Placebo
18 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
19 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
20 An Exploratory Study Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar I and II Patients From Valproic Acid to Depakote ER Completed NCT00211250 Phase 4 Valproic Acid and Depakote ER
21 The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff Completed NCT01462058 Phase 4 Placebo
22 Clinical Study of Flupentixol and Melitracen Tablets in the Treatment of Non Random Emotional Disorder Completed NCT04970667 Phase 4 Flupentixol melitracen tablets
23 Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial Completed NCT01431092 Phase 4 Placebo;Melatonin
24 An Open-Label Clinical Trial Conducted Via Telepsychiatry of Complementary and Alternative Treatments (Omega-3 Fatty Acids and Inositol vs. N-acetylcysteine) for the Management of Emotional Dysregulation in Youth Recruiting NCT03911414 Phase 4 Open-label Treatment with Omega-3 Fatty Acids + Inositol;Open-label Treatment with N-acetylcysteine
25 Bazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial Recruiting NCT04113993 Phase 4 Bazedoxifene Acetate;Placebo
26 Anti-inflmmation Treatment in Mood Disorder and Deep Learning Prediction Model Recruiting NCT04685642 Phase 4 Aspirin;Atorvastatin
27 Multi-modal Assessment of GABA Function in Psychosis Recruiting NCT04004416 Phase 4 Lorazepam and fMRI
28 A Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective Disorder Terminated NCT02140788 Phase 4 Metformin;Fish Oil
29 EnBrace HR for Premenstrual Syndrome (PMS) With Prominent Mood Symptoms (or Menstrual Related Mood Disorders, MRMD) Withdrawn NCT04123483 Phase 4 EnBrace HR Softgel
30 Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders (#6559R) [Formerly #5723] Withdrawn NCT03278938 Phase 4 bupropion;citalopram
31 Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury Completed NCT00704379 Phase 2, Phase 3 Placebo;Sertraline
32 A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents Completed NCT00221468 Phase 3 quetiapine
33 Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression: A Factorial Design Randomised Controlled Trial Completed NCT02703363 Phase 3 Minocycline;Celecoxib;Placebo
34 First Experimental Study of Transference Interpretations (FEST) Completed NCT00423462 Phase 2, Phase 3
35 A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension Completed NCT00035802 Phase 3 Topiramate;Placebo
36 Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes in Bipolar Disorder Completed NCT00309699 Phase 3 Placebo;Quetiapine;Paliperidone ER
37 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release Paliperidone in the Treatment of Subjects With Acute Manic and Mixed Episodes Associated With Bipolar I Disorder Completed NCT00299715 Phase 3 Paliperidone extended-release
38 A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension Completed NCT00240721 Phase 3 topiramate
39 Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms Completed NCT00202514 Phase 2, Phase 3 divalproex sodium extended release
40 An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects With a Mood Disorder Completed NCT00579982 Phase 3 Lamotrigine
41 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial Completed NCT01360645 Phase 3 OPC-34712 + ADT;Placebo + ADT
42 A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial Completed NCT01360866 Phase 3 OPC-34712;Escitalopram;Fluoxetine;Paroxetine CR;Sertraline;Duloxetine;Venlafaxine XR
43 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPDC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Polaris Trial Completed NCT01360632 Phase 3 OPC-34712 + ADT;Placebo + ADT
44 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress Completed NCT02196506 Phase 3 Placebo + ADT;Brexpiprazole +ADT
45 A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial Completed NCT01727726 Phase 3 Brexpiprazole;Seroquel XR;Placebo
46 A Multicenter, Randomized Controlled Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD) Completed NCT00809523 Phase 2, Phase 3
47 Reducing the Burden of Chronic Psychotic Disorders in Tanzania Completed NCT04327843 Phase 3 Haloperidol Decanoate
48 Magnetic Seizure Therapy (MST) for the Treatment of Severe Mood Disorder Completed NCT00488748 Phase 3
49 A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Determine Efficacy and Safety of BXCL501 In Agitation Associated With Schizophrenia Completed NCT04268303 Phase 3 Sublingual film containing dexmedetomidine (BXCL501);Placebo Film
50 Prevention of Seasonal Affective Disorder Completed NCT00046449 Phase 3 Investigational Seasonal Affective Disorder (SAD) Drug

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Divalproex Sodium
lamotrigine
Mood Stabilizer [EPC]
Sodium Valproate
Valproic Acid

Cochrane evidence based reviews: mood disorders

Sources

Genetic Tests for Mood Disorder

About this section
Sources

Anatomical Context for Mood Disorder

About this section

Organs/tissues related to Mood Disorder:

MalaCards : Brain, Heart, Pituitary, Prefrontal Cortex, Amygdala, Cingulate Cortex, Cortex
Sources

Publications for Mood Disorder

About this section

Articles related to Mood Disorder:

(show top 50) (show all 19927)
# Title Authors PMID Year
1
Pexidartinib (PLX3397) through restoring hippocampal synaptic plasticity ameliorates social isolation-induced mood disorders. 62 41
36395673 2022
2
Clinicians' Emotional Reactions toward Patients with Depressive Symptoms in Mood Disorders: A Narrative Scoping Review of Empirical Research. 62 41
36430122 2022
3
Emotions and arithmetic in children. 41
36456641 2022
4
Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. 53 62
20060128 2010
5
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 53 62
19936882 2010
6
Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. 53 62
20072116 2010
7
Altered gene expression of histone deacetylases in mood disorder patients. 53 62
19767015 2010
8
Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. 53 62
20043006 2010
9
Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. 53 62
19931869 2010
10
Culture-gene coevolution of individualism-collectivism and the serotonin transporter gene. 53 62
19864286 2010
11
Meta-analysis of the association between the monoamine oxidase-A gene and mood disorders. 53 62
20010318 2010
12
A possible role of neuropeptide Y in depression and stress. 53 62
19782662 2010
13
Genetic linkage of region containing the CREB1 gene to depressive disorders in families with recurrent, early-onset, major depression: a re-analysis and confirmation of sex-specific effect. 53 62
19517574 2010
14
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. 53 62
20016223 2010
15
Endocannabinoids and their role in fatty liver disease. 53 62
20460921 2010
16
kappa-Opioid receptor signaling and brain reward function. 53 62
19804796 2009
17
Altered expression and modulation of activity-regulated cytoskeletal associated protein (Arc) in serotonin transporter knockout rats. 53 62
19576731 2009
18
G72/G30 (DAOA) and juvenile-onset mood disorders. 53 62
19089835 2009
19
Relationships between angry-impulsive personality traits and genetic polymorphisms of the dopamine transporter. 53 62
19368898 2009
20
Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. 53 62
19584773 2009
21
A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. 53 62
19589503 2009
22
The role of beta-endorphin in the pathophysiology of major depression. 53 62
19647870 2009
23
Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning. 53 62
19906241 2009
24
Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. 53 62
19376528 2009
25
Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. 53 62
19375869 2009
26
Mutation screen and association analysis of the glucocorticoid receptor gene (NR3C1) in childhood-onset mood disorders (COMD). 53 62
19089807 2009
27
Management of non-motor complications in Parkinson's disease. 53 62
19711120 2009
28
Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. 53 62
19224106 2009
29
Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. 53 62
19375070 2009
30
Increased risk of suicide attempt in mood disorders and TPH1 genotype. 53 62
18977032 2009
31
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. 53 62
19233297 2009
32
Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. 53 62
19428704 2009
33
Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis. 53 62
19530966 2009
34
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. 53 62
19361869 2009
35
Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates. 53 62
18817811 2009
36
Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress. 53 62
18317463 2009
37
Partial regulation of serotonin transporter function by gamma-synuclein. 53 62
19429025 2009
38
Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder. 53 62
18704093 2009
39
Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. 53 62
18715570 2009
40
Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. 53 62
18849121 2009
41
[BDNF measurement in stress-related mood disorders: a review of clinical studies]. 53 62
20013430 2009
42
Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. 53 62
18976638 2009
43
Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population. 53 62
19224413 2009
44
Circadian polymorphisms associated with affective disorders. 53 62
19166596 2009
45
Disruption of the circadian timing systems: molecular mechanisms in mood disorders. 53 62
19708722 2009
46
Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. 53 62
19018231 2008
47
Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. 53 62
18574609 2008
48
The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: results of meta-analyses. 53 62
19032713 2008
49
BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. 53 62
19018714 2008
50
Increased expression of splicing factor SRp20 mRNA in bipolar disorder patients. 53 62
18281098 2008
Sources

Variations for Mood Disorder

About this section
Sources

Expression for Mood Disorder

About this section
Search GEO for disease gene expression data for Mood Disorder.
Sources

Pathways for Mood Disorder

About this section

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.65 BDNF CNR1 CREB1 CRH DRD2 DRD4
2
GPCR downstream signalling 66
Show member pathways
 13.48 TACR1 NPY HTR2A HTR1B HTR1A DRD4
3
Class A/1 (Rhodopsin-like receptors) 66
Show member pathways
 13.28 TACR1 NPY HTR2A HTR1B HTR1A DRD4
4
Neuroscience 3
12.46 TPH2 TPH1 TH NPY HTR1A CREB1
5
superpathway of tryptophan utilization 61
Show member pathways
 12.15 TPH2 TPH1 MAOB MAOA
6
Fragile X syndrome 74
Show member pathways
 11.9 CREB1 CNR1 BDNF
7
Monoamine GPCRs 74
Show member pathways
 11.87 HTR2A HTR1B HTR1A DRD4 DRD2
8
Sudden infant death syndrome (SIDS) susceptibility pathways 74
11.86 TPH2 TPH1 TH TACR1 SLC6A4 MAOA
9
GPCRs, other 74
11.79 HTR2A DRD4 CNR1
10
Amino acid metabolism 74
Show member pathways
 11.76 TPH1 TH MAOA
11
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 60
Show member pathways
 11.6 TH DRD4 DRD2
12
Monoamine transport 74
Show member pathways
 11.41 TPH2 TH SLC6A4 MAOA
13
Common pathways underlying drug addiction 74
Show member pathways
 11.38 DRD4 DRD2 CREB1
14
Biogenic amine synthesis 74
Show member pathways
 11.34 COMT MAOA MAOB TH TPH1 TPH2
15
Metabolism of amine-derived hormones 66
Show member pathways
 11.24 TPH2 TPH1 TH
16
Serotonin and anxiety 74
Show member pathways
 11.19 HTR2A HTR1A CRH
17
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
11.15 TPH2 TPH1 SLC6A4 MAOA HTR2A HTR1B
18
Neurotransmitter clearance 66
Show member pathways
 11.11 COMT MAOA SLC6A4
19
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
11 TH NPY DRD2
20
Tyrosine metabolism p.1 (dopamine) 22
10.96 TH MAOB MAOA COMT
21
p38 signaling mediated by MAPKAP kinases 61
10.8 TH CREB1
22
ERK pathway in Huntington's disease 74
10.79 CREB1 BDNF
23
Dopamine metabolism 74
10.78 TH MAOB MAOA COMT
24
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.68 TPH2 TH SLC6A4 MAOB MAOA HTR1B
25
serotonin and melatonin biosynthesis 66 61
10.6 TPH2 TPH1
26
dopamine degradation 61
10.27 MAOA COMT
Sources

GO Terms for Mood Disorder

About this section

Cellular components related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.45 CNR1 DRD2 DRD4 HTR1A HTR1B HTR2A
2 plasma membrane GO:0005887 10.45 CNR1 DRD2 DRD4 HTR1A HTR1B HTR2A
3 synapse GO:0045202 10.06 CNR1 CRH DISC1 DRD2 HTR1A HTR2A
4 axon GO:0030424 10.03 TH HTR2A DRD2 DISC1 COMT CNR1
5 GABA-ergic synapse GO:0098982 9.91 NPY DRD2 DISC1 CNR1
6 dendrite GO:0030425 9.91 TH TACR1 HTR2A HTR1B HTR1A DRD4
7 presynapse GO:0098793 9.8 SLC6A4 HTR2A DISC1 CNR1
8 G protein-coupled serotonin receptor complex GO:0098666 9.78 HTR2A HTR1B
9 serotonergic synapse GO:0099154 9.71 SLC6A4 HTR1B
10 obsolete integral component of postsynaptic membrane GO:0099055 9.63 SLC6A4 HTR2A DRD2
11 presynaptic membrane GO:0042734 9.63 CNR1 DRD2 HTR1B HTR2A SLC6A4
12 obsolete integral component of presynaptic membrane GO:0099056 9.02 SLC6A4 HTR2A HTR1B DRD2 CNR1

Biological processes related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.44 BDNF CNR1 CREB1 CRH DRD2 DRD4
2 chemical synaptic transmission GO:0007268 10.3 NPY HTR2A HTR1B HTR1A DRD4 CRH
3 response to xenobiotic stimulus GO:0009410 10.28 CREB1 DRD2 HTR2A MAOB SLC6A4 TH
4 circadian rhythm GO:0007623 10.18 TPH2 TPH1 SLC6A4 CREB1
5 positive regulation of fat cell differentiation GO:0045600 10.16 TPH1 HTR2A CREB1
6 social behavior GO:0035176 10.16 TH SLC6A4 DRD4
7 response to amphetamine GO:0001975 10.12 TH DRD4 DRD2
8 response to cocaine GO:0042220 10.11 HTR1B DRD2 CNR1
9 negative regulation of blood pressure GO:0045776 10.11 CNR1 DRD2 NPY
10 regulation of dopamine secretion GO:0014059 10.1 HTR2A HTR1B DRD2
11 response to electrical stimulus GO:0051602 10.1 TH TACR1 DISC1
12 sensory perception of pain GO:0019233 10.08 CNR1 HTR2A TACR1
13 response to morphine GO:0043278 10.07 CNR1 DRD2 TACR1
14 dopamine metabolic process GO:0042417 10.04 DRD4 DRD2 COMT
15 behavioral response to cocaine GO:0048148 10.02 HTR2A DRD4 DRD2
16 response to nicotine GO:0035094 10.02 CNR1 DRD2 TACR1 TH
17 regulation of dopamine metabolic process GO:0042053 10 HTR1A DRD4
18 regulation of behavior GO:0050795 10 HTR1B HTR1A
19 behavioral response to ethanol GO:0048149 10 DRD4 DRD2
20 G protein-coupled serotonin receptor signaling pathway GO:0098664 10 HTR2A HTR1A DRD4
21 response to ethanol GO:0045471 10 CNR1 DRD2 HTR1B MAOB TACR1 TH
22 positive regulation of hormone secretion GO:0046887 9.99 TACR1 CREB1
23 drinking behavior GO:0042756 9.99 HTR1B DRD2
24 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.99 HTR2A HTR1B DRD2
25 hyaloid vascular plexus regression GO:1990384 9.98 TH DRD2
26 serotonin receptor signaling pathway GO:0007210 9.98 HTR2A HTR1A
27 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.97 HTR1B HTR1A
28 sperm ejaculation GO:0042713 9.97 TACR1 SLC6A4
29 cellular response to alkaloid GO:0071312 9.97 TH HTR1B
30 positive regulation of dopamine metabolic process GO:0045964 9.96 NPY MAOB
31 negative regulation of dopamine secretion GO:0033602 9.96 DRD2 CNR1
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.95 DRD4 DRD2
33 feeding behavior GO:0007631 9.95 NPY HTR1B DRD2
34 dopamine catabolic process GO:0042420 9.93 MAOB MAOA COMT
35 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.92 DRD4 DRD2
36 serotonin biosynthetic process GO:0042427 9.91 TPH2 TPH1
37 response to histamine GO:0034776 9.91 DRD4 DRD2
38 neurotransmitter catabolic process GO:0042135 9.91 MAOB MAOA COMT
39 regulation of synaptic vesicle exocytosis GO:2000300 9.89 NPY HTR2A HTR1B DRD2
40 presynaptic modulation of chemical synaptic transmission GO:0099171 9.88 HTR2A HTR1B DRD2
41 regulation of presynaptic cytosolic calcium ion concentration GO:0099509 9.86 NPY HTR1B CNR1
42 negative regulation of serotonin secretion GO:0014063 9.8 MAOB HTR1B CNR1
43 aromatic amino acid metabolic process GO:0009072 9.77 TPH2 TPH1 TH
44 memory GO:0007613 9.73 TH SLC6A4 HTR2A CREB1 CNR1 BDNF
45 regulation of biological quality GO:0065008 9.71 DRD4 DRD2
46 catecholamine metabolic process GO:0006584 9.7 MAOA COMT
47 synaptic transmission, dopaminergic GO:0001963 9.7 TH DRD4 DRD2 CRH
48 behavior GO:0007610 9.58 HTR2A HTR1B HTR1A
49 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.4 NPY HTR2A HTR1B HTR1A DRD4 CNR1

Molecular functions related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 10.11 CNR1 DRD2 DRD4 HTR1A HTR1B HTR2A
2 neurotransmitter receptor activity GO:0030594 10.01 HTR2A HTR1B HTR1A DRD4
3 primary amine oxidase activity GO:0008131 9.83 MAOB MAOA
4 phenethylamine:oxygen oxidoreductase (deaminating) activity GO:0052596 9.8 MAOB MAOA
5 monoamine oxidase activity GO:0097621 9.78 MAOB MAOA
6 aliphatic amine oxidase activity GO:0052595 9.76 MAOB MAOA
7 G protein-coupled serotonin receptor activity GO:0004993 9.76 HTR2A HTR1B HTR1A DRD4
8 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.73 DRD4 DRD2
9 dopamine binding GO:0035240 9.73 TH DRD4 DRD2
10 dopamine neurotransmitter receptor activity GO:0004952 9.69 DRD4 DRD2
11 tryptophan 5-monooxygenase activity GO:0004510 9.62 TPH2 TPH1
12 serotonin binding GO:0051378 9.23 SLC6A4 HTR2A HTR1B HTR1A
13 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.13 TPH2 TPH1 TH
Sources

Sources for Mood Disorder

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....